Secondaries announced 10.5.2016
IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: Idera Pharmaceuticals Symbol: IDRA Price: Last trade $2.61 Trade Date: 10/7 Shares: 19.2 million Underwriter(s)J.P. Morgan, Goldman Sachs Rating=Subscription Needed